Coronary Artery Disease
DES in CTO: Cosmetic or clinical benefit†
B.K. Goyal MD, FAMS, FRCD, FSCAI, FACC,
Corresponding Author
B.K. Goyal MD, FAMS, FRCD, FSCAI, FACC
Director Interventional Cardiology, Bombay Hospital & Medical Research Center
Bombay Hospital Institute of Medical Sciences, 12, New Marine Lines, Mumbai 400020, India
Search for more papers by this author
B.K. Goyal MD, FAMS, FRCD, FSCAI, FACC,
Corresponding Author
B.K. Goyal MD, FAMS, FRCD, FSCAI, FACC
Director Interventional Cardiology, Bombay Hospital & Medical Research Center
Bombay Hospital Institute of Medical Sciences, 12, New Marine Lines, Mumbai 400020, India
Search for more papers by this author
First published: 24 March 2009
No abstract is available for this article.
REFERENCES
- 1
Dzavik V, Buller CE, Lamas GA, Rankin JM,Mancini GB, Cantor WJ, Carere RJ,Ross JR, Atchison D,Forman S, et al.
Randomized trial of percutaneous coronary intervention for subacute infarct-related coronary artery occlusion to achieve long-term patency and improve ventricular function: the Total Occlusion Study of Canada (TOSCA)-2 trial.
Circulation
2006;
114:
2449–2457.
- 2
Suttorp MJ, Laarman GJ, Rahel BM, et al.
Primary stenting of Totally Occluded Native Coronary ArteriesII (PRISON II): A randomized comparison of bare metal stent implantation with sirolimus-eluting stent implantation for the treatment of total coronary occlusions.
Circulation
2006;
114:
921–928.
- 3
Werner GS, Krack A, Schwarz G, Prochnau D, Betge S, Figulla HR.
Prevention of lesion recurrence in CTO by paclitaxel-eluting stens.
J Am Coll Cardiol
2004;
44:
2301–2306.
- 4
Olivari Z, Rubartelli P, Piscione F, et al.
Immediate results and one-year clinical outcome after percutaneous coronary intervention in CTO; data from a multicenter, prospective, observational study (TOAST-GISE).
J Am Coll Cardiol
2003;
41:
1672–1678.
